162 related articles for article (PubMed ID: 17989105)
1. Clinical and histological responses of renal amyloidosis to high-dose melphalan supported by autologous stem cell transplantation.
Sanada S; Suzuki M; Shindo T; Suzuki S; Nakamichi T; Matsubara M; Maeda K
Nephrol Dial Transplant; 2008 Feb; 23(2):747-50. PubMed ID: 17989105
[No Abstract] [Full Text] [Related]
2. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.
Leung N; Dispenzieri A; Fervenza FC; Lacy MQ; Villicana R; Cavalcante JL; Gertz MA
Am J Kidney Dis; 2005 Aug; 46(2):270-7. PubMed ID: 16112045
[TBL] [Abstract][Full Text] [Related]
3. Recovery of acute renal failure and nephrotic syndrome following autologous stem cell transplantation for primary (AL) amyloidosis.
Snanoudj R; Mamzer-Bruneel MF; Hermine O; Grunfeld JP; Chauveau D
Nephrol Dial Transplant; 2003 Oct; 18(10):2175-7. PubMed ID: 13679499
[No Abstract] [Full Text] [Related]
4. Marked recovery of severe renal lesions in POEMS syndrome with high-dose melphalan therapy supported by autologous blood stem cell transplantation.
Sanada S; Ookawara S; Karube H; Shindo T; Goto T; Nakamichi T; Saito M; Matsubara M; Suzuki M
Am J Kidney Dis; 2006 Apr; 47(4):672-9. PubMed ID: 16564945
[TBL] [Abstract][Full Text] [Related]
5. Successful reduced intensity allogeneic stem cell transplantation for systemic AL amyloidosis.
Imamura T; Ogata M; Kohno K; Tomo T; Ohtsuka E; Kikuchi H; Kadota J
Am J Hematol; 2006 Apr; 81(4):281-3. PubMed ID: 16550508
[TBL] [Abstract][Full Text] [Related]
6. Early intensification and autologous stem cell transplantation in patients with systemic AL amyloidosis: a single-centre experience.
Frossard V; Ketterer N; Rosselet A; Meier P; Cairoli A; Duchosal MA; Kovacsovics T
Ann Hematol; 2009 Jul; 88(7):681-5. PubMed ID: 19066891
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment of systemic amyloidosis with hepatic involvement and factor X deficiency by high dose melphalan chemotherapy and autologous stem cell reinfusion.
Breems DA; Sonneveld P; de Man RA; Leebeek FW
Eur J Haematol; 2004 Mar; 72(3):181-5. PubMed ID: 14962236
[TBL] [Abstract][Full Text] [Related]
8. Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis.
Sanchorawala V; Wright DG; Quillen K; Finn KT; Dember LM; Berk JL; Doros G; Fisher C; Skinner M; Seldin DC
Bone Marrow Transplant; 2007 Sep; 40(6):557-62. PubMed ID: 17589534
[TBL] [Abstract][Full Text] [Related]
9. High-dose melphalan and autologous stem cell transplantation for systemic light-chain amyloidosis: a single institution retrospective analysis of 40 cases.
Tsukada N; Ikeda M; Shingaki S; Miyazaki K; Meshitsuka S; Yoshiki Y; Abe Y; Suzuki K
Int J Hematol; 2016 Mar; 103(3):299-305. PubMed ID: 26703787
[TBL] [Abstract][Full Text] [Related]
10. Modern treatment of amyloidosis: unresolved questions.
Dember LM
J Am Soc Nephrol; 2009 Mar; 20(3):469-72. PubMed ID: 19073820
[TBL] [Abstract][Full Text] [Related]
11. [High-dose treatment of systemic AL-amyloidosis with autologous stem cell support].
Schjesvold FH; Sjo M; Tangen JM; Hammerstrøm J; Brinch L
Tidsskr Nor Laegeforen; 2008 Jun; 128(12):1392-6. PubMed ID: 18552900
[TBL] [Abstract][Full Text] [Related]
12. An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis.
Sanchorawala V; Seldin DC
Amyloid; 2007 Dec; 14(4):261-9. PubMed ID: 17968685
[TBL] [Abstract][Full Text] [Related]
13. [Advances in diagnosis and treatment of AL amyloidosis].
Zelichowski G; Lubas A; Wańkowicz Z
Pol Merkur Lekarski; 2008 Apr; 24(142):340-5. PubMed ID: 18634370
[TBL] [Abstract][Full Text] [Related]
14. Renal amyloidosis: pathogenesis and therapy.
Jones NF
Clin Nephrol; 1976 Nov; 6(5):459-64. PubMed ID: 136327
[No Abstract] [Full Text] [Related]
15. Clinical and molecular characteristics of patients with non-amyloid light chain deposition disorders, and outcome following treatment with high-dose melphalan and autologous stem cell transplantation.
Weichman K; Dember LM; Prokaeva T; Wright DG; Quillen K; Rosenzweig M; Skinner M; Seldin DC; Sanchorawala V
Bone Marrow Transplant; 2006 Sep; 38(5):339-43. PubMed ID: 16862166
[TBL] [Abstract][Full Text] [Related]
16. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
Lachmann HJ; Wechalekar AD; Gillmore JD
N Engl J Med; 2008 Jan; 358(1):91-2; author reply 92-3. PubMed ID: 18175386
[No Abstract] [Full Text] [Related]
17. AL amyloidosis associated with B-cell lymphoproliferative disorders: frequency and treatment outcomes.
Sanchorawala V; Blanchard E; Seldin DC; O'Hara C; Skinner M; Wright DG
Am J Hematol; 2006 Sep; 81(9):692-5. PubMed ID: 16795060
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of amyloidosis].
Wien TN
Tidsskr Nor Laegeforen; 2008 Jun; 128(12):1397-400. PubMed ID: 18552901
[TBL] [Abstract][Full Text] [Related]
19. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
Comenzo RL; Steingart RM; Cohen AD
N Engl J Med; 2008 Jan; 358(1):92; author reply 92-3. PubMed ID: 18175384
[No Abstract] [Full Text] [Related]
20. Renal amyloidosis.
Jazbeh S; Said A; Haddad RY; Hamad A; Lerma EV
Dis Mon; 2014 Oct; 60(10):489-93. PubMed ID: 25280992
[No Abstract] [Full Text] [Related]
[Next] [New Search]
